Aptorum Group Ltd
NASDAQ:APM
Aptorum Group Ltd
Research & Development
Aptorum Group Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aptorum Group Ltd
NASDAQ:APM
|
Research & Development
-$393.7k
|
CAGR 3-Years
66%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Research & Development
-$150.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-104%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Research & Development
-$238.3m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Research & Development
-$119m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Research & Development
-£15.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Research & Development
£9.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Aptorum Group Ltd
Glance View
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.
See Also
What is Aptorum Group Ltd's Research & Development?
Research & Development
-393.7k
USD
Based on the financial report for Dec 31, 2024, Aptorum Group Ltd's Research & Development amounts to -393.7k USD.
What is Aptorum Group Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
44%
Over the last year, the Research & Development growth was 89%. The average annual Research & Development growth rates for Aptorum Group Ltd have been 66% over the past three years , 44% over the past five years .
